Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.

Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK.

Cancer Biol Ther. 2010 Feb;9(3):176-82. Epub 2010 Feb 16.

2.

Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.

Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, Spannuth W, Arumugam T, Han LY, Jennings NB, Logsdon C, Jaffe RB, Coleman RL, Sood AK.

Clin Cancer Res. 2007 Jul 15;13(14):4209-17.

3.

Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.

Kim TJ, Landen CN, Lin YG, Mangala LS, Lu C, Nick AM, Stone RL, Merritt WM, Armaiz-Pena G, Jennings NB, Coleman RL, Tice DA, Sood AK.

Cancer Biol Ther. 2009 Dec;8(23):2263-72. Epub 2009 Dec 19.

4.

Two is better than one: benefits of VEGF and PDGF inhibition in ovarian cancer.

Sennino B.

Cancer Biol Ther. 2010 Feb;9(3):183-5. Epub 2010 Feb 4. No abstract available.

PMID:
20083903
5.

Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102.

Sennino B, Falcón BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM.

Cancer Res. 2007 Aug 1;67(15):7358-67.

6.

Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.

Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK.

Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028.

7.

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.

Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.

J Natl Cancer Inst. 2006 Nov 1;98(21):1558-70.

8.

Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.

Hasumi Y, Kłosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C.

Int J Cancer. 2007 Dec 15;121(12):2606-14.

9.

Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.

Falcon BL, Pietras K, Chou J, Chen D, Sennino B, Hanahan D, McDonald DM.

Am J Pathol. 2011 Jun;178(6):2920-30. doi: 10.1016/j.ajpath.2011.02.019.

10.

Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Merritt WM, Nick AM, Carroll AR, Lu C, Matsuo K, Dumble M, Jennings N, Zhang S, Lin YG, Spannuth WA, Kamat AA, Stone RL, Shahzad MM, Coleman RL, Kumar R, Sood AK.

Mol Cancer Ther. 2010 Apr;9(4):985-95. doi: 10.1158/1535-7163.MCT-09-0967. Epub 2010 Apr 6.

11.

Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.

Moreno-Smith M, Lee SJ, Lu C, Nagaraja AS, He G, Rupaimoole R, Han HD, Jennings NB, Roh JW, Nishimura M, Kang Y, Allen JK, Armaiz GN, Matsuo K, Shahzad MM, Bottsford-Miller J, Langley RR, Cole SW, Lutgendorf SK, Siddik ZH, Sood AK.

Neoplasia. 2013 May;15(5):502-10.

12.
13.

A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.

Tsujioka H, Fukami T, Yotsumoto F, Ueda T, Hikita S, Takahashi Y, Kondo H, Kuroki M, Miyamoto S.

Anticancer Res. 2011 Jul;31(7):2461-5.

PMID:
21873160
14.

Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.

Navis AC, Hamans BC, Claes A, Heerschap A, Jeuken JW, Wesseling P, Leenders WP.

J Pathol. 2011 Apr;223(5):626-34. doi: 10.1002/path.2836. Epub 2011 Feb 21.

PMID:
21341272
15.

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.

16.
17.

Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.

Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL, Sood AK.

Cancer Res. 2007 Jan 1;67(1):281-8.

19.

Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.

Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK.

Neoplasia. 2008 Nov;10(11):1259-67.

20.

Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.

Mabuchi S, Terai Y, Morishige K, Tanabe-Kimura A, Sasaki H, Kanemura M, Tsunetoh S, Tanaka Y, Sakata M, Burger RA, Kimura T, Ohmichi M.

Clin Cancer Res. 2008 Dec 1;14(23):7781-9. doi: 10.1158/1078-0432.CCR-08-0243.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk